Myriad Genetics (MYGN) Invested Capital (2010 - 2026)

Myriad Genetics has disclosed Invested Capital across 17 years of filings, most recently posting $457.7 million for Q1 2026.

• In Q1 2026, Invested Capital fell 40.11% year-over-year to $457.7 million; the TTM figure through Mar 2026 stood at $457.7 million (down 40.11% YoY), while the FY2025 annual figure was $487.9 million, down 34.13% from the prior year.
• Invested Capital declined to $457.7 million in Q1 2026, from $487.9 million in the prior quarter.
• Over the last five years, Invested Capital for MYGN reached as high as $950.1 million in Q1 2022 and fell as low as $447.5 million in Q2 2025.
• The 5-year median for Invested Capital is $775.2 million (2023), against an average of $741.1 million.
• Annual changes were most pronounced in 2024 — Invested Capital advanced 6.68% — and 2025, when it plunged 42.66%.
• A 5-year view of Invested Capital shows it stood at $885.8 million in 2022, then slipped by 7.24% to $821.7 million in 2023, then fell by 9.86% to $740.7 million in 2024, then plunged by 34.13% to $487.9 million in 2025, then declined by 6.19% to $457.7 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $457.7 million, $487.9 million, and $492.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.